Publication
The European Commission’s prohibition of Illumina's acquisition of GRAIL
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the adm...
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the adm...
Publication
In November 2023, the UK Competition & Markets Authority (CMA) released its Prioritisation statement on combination ther...
Publication
In late 2020, following almost 18 months of public and industry consultations conducted by the Therapeutic Goods Adminis...
Publication
On 6 September 2022, the European Commission (EC) prohibited Illumina’s acquisition of Grail, bringing to an end the adm...
Publication
In November 2023, the UK Competition & Markets Authority (CMA) released its Prioritisation statement on combination ther...
© Norton Rose Fulbright LLP 2023